Mode
Text Size
Log in / Sign up
N/A N=30 Treatment

Clinical Evaluation of the Safety and Efficacy of a 1060 nm Diode Laser (Flanks)

Fat Atrophy

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: Change in the Percentage of Fat Thickness From Baseline to 12-weeks Post-treatment — -6.9 percentage of body fat

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
1060nm Diode laser (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Venus Concept
Primary completion
Jul 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in the Percentage of Fat Thickness From Baseline to 12-weeks Post-treatment
-6.9
SECONDARY
Change in Abdominal Circumference From Baseline to 12 Weeks Post-treatment
-0.87
SECONDARY
Subject Satisfaction
3.3
SECONDARY
Treatment Pain
3.1

Summary

The objective of this clinical study is to assess the safety and efficacy of using a 1060 nm diode laser for non-invasive fat reduction of the flanks.

Eligibility Criteria

Inclusion Criteria

  • able to read, understand and voluntarily provide written informed consent
  • healthy male or female > 18 years of age seeking treatment for unwanted fat in the abdomen
  • BMI score is less then 30
  • agree to not making any major changes in their diet or lifestyle during the course of the study
  • able and willing to comply with the treatment / follow up schedule and requirements
  • women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrolment and for the duration of the study, have a negative urine pregnancy test baseline

Exclusion Criteria

  • pregnant in the last 3 months intending to become pregnant, postpartum or nursing in the last 6 months
  • any previous liposuction / lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months
  • history of immunosuppression / immune deficiency disorders including AIDS and HIV infection, or use of immunosuppressive medications, 6 month prior to and during the course of the study
  • History of hyperlipidemia, diabetes, hepatitis, blood coagulopathy or excessive bleeding
  • Use of antiplatelet medications (81 mg of acetylsalicylic acid daily is permitted), anticoagulants, thrombocytes or any-inflammatory medications within 2 weeks of treatment
  • Having a history of skin cancer or any other cancer in the area to be treated, including presence of malignant or pre-malignant pigmented lesions
  • Having a permanent implant in the treatment area such as a metal plate or injected chemical substance such as silicone pr parenteral gold therapy (gold sodium thiomalate)
  • Use of medications, herbs or food supplements and vitamins known to induce photosensitivity to light exposure at the wavelength used history of photosensitivity disorder
  • Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections
  • Tattoos in the treatment area
  • Poor quality skin (laxity)
  • Abdominal wall, muscular abnormality or hernia on physical examination
  • Unstable weight within the last 6 months (+ or - 3% weight change in the prior six months)
  • Participation in another clinical study involving the same anatomical areas within the last 6 months
  • History of keloid and hypertrophic scar formation or poor wound healing in the treatment area
  • As per the investigators discretion any physician or mental condition which may make it unsafe for the subject to participate
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03756168). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search